Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Akeso Reports Positive Data from PD-1/CTLA-4 Bispecific Published in Lancet

publication date: Oct 13, 2023

Guangzhou Akeso announced that positive results from a Phase Ib/II clinical trial of cadonilimab, a PD-1/CTLA-4 bispecific antibody, were published in The Lancet Oncology. Akeso said the trial was the first PD-1/CTLA-4 dual immune checkpoint inhibitor to be trialed for solid tumors. Cadonilimab binds different cells that express PD-1 or CTLA-4, reducing the activation of immunosuppressive pathways while increasing the T-cell-mediated immune response. Cadonilimab is the first-in-class PD-1/CTLA-4 bispecific antibody developed in China. More details....

Stock Symbol: (HK: 9926)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here

BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here

Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here